Vestibular Schwannoma Growth with Aspirin and Other Nonsteroidal Anti-inflammatory Drugs

Jacob B. Hunter, Brendan P. O'Connell, George B. Wanna, Marc L. Bennett, Alejandro Rivas, Reid C. Thompson, David S. Haynes

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To investigate whether the use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) impact the growth of vestibular schwannoma (VS). Study Design: Retrospective case series. Setting: Single academic, tertiary care center. Patients: Patients with VS who underwent at least two magnetic resonance imaging (MRI) studies before intervention. Intervention(s): Serial MRI studies. Main Outcome Measure(s): VS tumor growth, defined as more than or equal to 2mm increase in the maximum tumor diameter between consecutive MRI studies, or between the first and last available study. Mean growth rate was also calculated, defined as the change in tumor size divided by length of follow-up. Results: A total of 564 VS patients met inclusion criteria, with 234 (41.2%) taking some type of NSAID. Aspirin use was not associated with VS tumor growth, presenting tumor diameter, or mean VS growth rate. Further, aspirin dosage did not impact growth outcomes or presenting tumor diameter. A total of 96 (17.0%) patients took an NSAID other than aspirin. Neither non-aspirin NSAID use nor degree of cyclooxygenase-2 (COX-2) selectivity, including aspirin, was significantly associated with VS tumor growth, presenting tumor diameter, or mean VS growth rate. Conclusions: While previous studies have suggested a relationship between aspirin usage and VS growth, we found no significant association in our series of 564 observed VS. Furthermore, there was no apparent relationship between aspirin dosage, non-aspirin NSAID use, and COX-2 selectivity with VS growth, presenting tumor diameter at presentation, or mean VS growth rate.

Original languageEnglish (US)
Pages (from-to)1158-1164
Number of pages7
JournalOtology and Neurotology
Volume38
Issue number8
DOIs
StatePublished - Sep 1 2017

Fingerprint

Acoustic Neuroma
Aspirin
Anti-Inflammatory Agents
Growth
Pharmaceutical Preparations
Neoplasms
Magnetic Resonance Imaging
Cyclooxygenase 2
Tertiary Care Centers
Retrospective Studies
Outcome Assessment (Health Care)

Keywords

  • Acoustic neuroma
  • Aspirin
  • Non-steroidal anti-inflammatory drug
  • NSAID
  • Observation
  • Vestibular schwannoma

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Sensory Systems
  • Clinical Neurology

Cite this

Hunter, J. B., O'Connell, B. P., Wanna, G. B., Bennett, M. L., Rivas, A., Thompson, R. C., & Haynes, D. S. (2017). Vestibular Schwannoma Growth with Aspirin and Other Nonsteroidal Anti-inflammatory Drugs. Otology and Neurotology, 38(8), 1158-1164. https://doi.org/10.1097/MAO.0000000000001506

Vestibular Schwannoma Growth with Aspirin and Other Nonsteroidal Anti-inflammatory Drugs. / Hunter, Jacob B.; O'Connell, Brendan P.; Wanna, George B.; Bennett, Marc L.; Rivas, Alejandro; Thompson, Reid C.; Haynes, David S.

In: Otology and Neurotology, Vol. 38, No. 8, 01.09.2017, p. 1158-1164.

Research output: Contribution to journalArticle

Hunter, JB, O'Connell, BP, Wanna, GB, Bennett, ML, Rivas, A, Thompson, RC & Haynes, DS 2017, 'Vestibular Schwannoma Growth with Aspirin and Other Nonsteroidal Anti-inflammatory Drugs', Otology and Neurotology, vol. 38, no. 8, pp. 1158-1164. https://doi.org/10.1097/MAO.0000000000001506
Hunter, Jacob B. ; O'Connell, Brendan P. ; Wanna, George B. ; Bennett, Marc L. ; Rivas, Alejandro ; Thompson, Reid C. ; Haynes, David S. / Vestibular Schwannoma Growth with Aspirin and Other Nonsteroidal Anti-inflammatory Drugs. In: Otology and Neurotology. 2017 ; Vol. 38, No. 8. pp. 1158-1164.
@article{6b07bfa5a46c44619f1d56382c9ea029,
title = "Vestibular Schwannoma Growth with Aspirin and Other Nonsteroidal Anti-inflammatory Drugs",
abstract = "Objective: To investigate whether the use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) impact the growth of vestibular schwannoma (VS). Study Design: Retrospective case series. Setting: Single academic, tertiary care center. Patients: Patients with VS who underwent at least two magnetic resonance imaging (MRI) studies before intervention. Intervention(s): Serial MRI studies. Main Outcome Measure(s): VS tumor growth, defined as more than or equal to 2mm increase in the maximum tumor diameter between consecutive MRI studies, or between the first and last available study. Mean growth rate was also calculated, defined as the change in tumor size divided by length of follow-up. Results: A total of 564 VS patients met inclusion criteria, with 234 (41.2{\%}) taking some type of NSAID. Aspirin use was not associated with VS tumor growth, presenting tumor diameter, or mean VS growth rate. Further, aspirin dosage did not impact growth outcomes or presenting tumor diameter. A total of 96 (17.0{\%}) patients took an NSAID other than aspirin. Neither non-aspirin NSAID use nor degree of cyclooxygenase-2 (COX-2) selectivity, including aspirin, was significantly associated with VS tumor growth, presenting tumor diameter, or mean VS growth rate. Conclusions: While previous studies have suggested a relationship between aspirin usage and VS growth, we found no significant association in our series of 564 observed VS. Furthermore, there was no apparent relationship between aspirin dosage, non-aspirin NSAID use, and COX-2 selectivity with VS growth, presenting tumor diameter at presentation, or mean VS growth rate.",
keywords = "Acoustic neuroma, Aspirin, Non-steroidal anti-inflammatory drug, NSAID, Observation, Vestibular schwannoma",
author = "Hunter, {Jacob B.} and O'Connell, {Brendan P.} and Wanna, {George B.} and Bennett, {Marc L.} and Alejandro Rivas and Thompson, {Reid C.} and Haynes, {David S.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1097/MAO.0000000000001506",
language = "English (US)",
volume = "38",
pages = "1158--1164",
journal = "Otology and Neurotology",
issn = "1531-7129",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Vestibular Schwannoma Growth with Aspirin and Other Nonsteroidal Anti-inflammatory Drugs

AU - Hunter, Jacob B.

AU - O'Connell, Brendan P.

AU - Wanna, George B.

AU - Bennett, Marc L.

AU - Rivas, Alejandro

AU - Thompson, Reid C.

AU - Haynes, David S.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objective: To investigate whether the use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) impact the growth of vestibular schwannoma (VS). Study Design: Retrospective case series. Setting: Single academic, tertiary care center. Patients: Patients with VS who underwent at least two magnetic resonance imaging (MRI) studies before intervention. Intervention(s): Serial MRI studies. Main Outcome Measure(s): VS tumor growth, defined as more than or equal to 2mm increase in the maximum tumor diameter between consecutive MRI studies, or between the first and last available study. Mean growth rate was also calculated, defined as the change in tumor size divided by length of follow-up. Results: A total of 564 VS patients met inclusion criteria, with 234 (41.2%) taking some type of NSAID. Aspirin use was not associated with VS tumor growth, presenting tumor diameter, or mean VS growth rate. Further, aspirin dosage did not impact growth outcomes or presenting tumor diameter. A total of 96 (17.0%) patients took an NSAID other than aspirin. Neither non-aspirin NSAID use nor degree of cyclooxygenase-2 (COX-2) selectivity, including aspirin, was significantly associated with VS tumor growth, presenting tumor diameter, or mean VS growth rate. Conclusions: While previous studies have suggested a relationship between aspirin usage and VS growth, we found no significant association in our series of 564 observed VS. Furthermore, there was no apparent relationship between aspirin dosage, non-aspirin NSAID use, and COX-2 selectivity with VS growth, presenting tumor diameter at presentation, or mean VS growth rate.

AB - Objective: To investigate whether the use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) impact the growth of vestibular schwannoma (VS). Study Design: Retrospective case series. Setting: Single academic, tertiary care center. Patients: Patients with VS who underwent at least two magnetic resonance imaging (MRI) studies before intervention. Intervention(s): Serial MRI studies. Main Outcome Measure(s): VS tumor growth, defined as more than or equal to 2mm increase in the maximum tumor diameter between consecutive MRI studies, or between the first and last available study. Mean growth rate was also calculated, defined as the change in tumor size divided by length of follow-up. Results: A total of 564 VS patients met inclusion criteria, with 234 (41.2%) taking some type of NSAID. Aspirin use was not associated with VS tumor growth, presenting tumor diameter, or mean VS growth rate. Further, aspirin dosage did not impact growth outcomes or presenting tumor diameter. A total of 96 (17.0%) patients took an NSAID other than aspirin. Neither non-aspirin NSAID use nor degree of cyclooxygenase-2 (COX-2) selectivity, including aspirin, was significantly associated with VS tumor growth, presenting tumor diameter, or mean VS growth rate. Conclusions: While previous studies have suggested a relationship between aspirin usage and VS growth, we found no significant association in our series of 564 observed VS. Furthermore, there was no apparent relationship between aspirin dosage, non-aspirin NSAID use, and COX-2 selectivity with VS growth, presenting tumor diameter at presentation, or mean VS growth rate.

KW - Acoustic neuroma

KW - Aspirin

KW - Non-steroidal anti-inflammatory drug

KW - NSAID

KW - Observation

KW - Vestibular schwannoma

UR - http://www.scopus.com/inward/record.url?scp=85022209392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022209392&partnerID=8YFLogxK

U2 - 10.1097/MAO.0000000000001506

DO - 10.1097/MAO.0000000000001506

M3 - Article

C2 - 28692590

AN - SCOPUS:85022209392

VL - 38

SP - 1158

EP - 1164

JO - Otology and Neurotology

JF - Otology and Neurotology

SN - 1531-7129

IS - 8

ER -